Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전호수 | * |
dc.date.accessioned | 2023-10-19T16:31:22Z | - |
dc.date.available | 2023-10-19T16:31:22Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 8159-9319 | * |
dc.identifier.other | OAK-34085 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/266323 | - |
dc.description.abstract | Background and Aim: Clinical features of non-alcoholic fatty liver disease (NAFLD), but not fulfilling the diagnostic criteria of metabolic dysfunction-associated fatty liver disease (MAFLD), remain unclear. We investigated the risk of sarcopenia and cardiovascular disease (CVD) in MAFLD and non-metabolic risk (MR) NAFLD. Methods: Subjects were selected from the Korean National Health and Nutrition Examination Surveys 2008–2011. Liver steatosis was assessed using fatty liver index. Significant liver fibrosis was defined using fibrosis-4 index, categorized by age cut-offs. Sarcopenia was defined as the lowest quintile sarcopenia index. Atherosclerotic CVD (ASCVD) risk score > 10% was defined as high probability. Results: A total of 7248 subjects had fatty liver (137 with non-MR NAFLD, 1752 with MAFLD/non-NAFLD, and 5359 with overlapping MAFLD and NAFLD). In non-MR NAFLD group 28 (20.4%) had significant fibrosis. The risk of sarcopenia (adjusted odds ratio [aOR] = 2.71, 95% confidence index [CI] = 1.27–5.78) and high probability of ASCVD (aOR = 2.79, 95% CI = 1.23–6.35) was significantly higher in MAFLD/non-NAFLD group than in non-MR NAFLD group (all P < 0.05). The risk of sarcopenia and high probability of ASCVD was similar between subjects with and without significant fibrosis in non-MR NAFLD group (all P > 0.05). However, the risk was significantly higher in MAFLD group than in non-MR NAFLD group (aOR = 3.38 for sarcopenia and 3.73 for ASCVD; all P < 0.05). Conclusions: The risks of sarcopenia and CVD were significantly higher in MAFLD group but did not differ according to fibrotic burden in non-MR NAFLD group. The MAFLD criteria might be better for identifying high-risk fatty liver disease than the NAFLD criteria. © 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. | * |
dc.language | English | * |
dc.publisher | John Wiley and Sons Inc | * |
dc.subject | Cardiovascular disease | * |
dc.subject | Liver fibrosis | * |
dc.subject | Metabolic dysfunction-associated fatty liver disease | * |
dc.subject | Non-alcoholic fatty liver disease | * |
dc.subject | Sarcopenia | * |
dc.title | MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study | * |
dc.type | Article | * |
dc.relation.issue | 9 | * |
dc.relation.volume | 38 | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1598 | * |
dc.relation.lastpage | 1609 | * |
dc.relation.journaltitle | Journal of Gastroenterology and Hepatology (Australia) | * |
dc.identifier.doi | 10.1111/jgh.16261 | * |
dc.identifier.scopusid | 2-s2.0-85161824734 | * |
dc.author.google | Han E. | * |
dc.author.google | Chun H.S. | * |
dc.author.google | Lee Y.-H. | * |
dc.author.google | Lee J.S. | * |
dc.author.google | Lee H.W. | * |
dc.author.google | Kim B.K. | * |
dc.author.google | Park J.Y. | * |
dc.author.google | Kim D.Y. | * |
dc.author.google | Lee B.-W. | * |
dc.author.google | Kang E.S. | * |
dc.author.google | Cha B.-S. | * |
dc.author.google | Ahn S.H. | * |
dc.author.google | Kim S.U. | * |
dc.contributor.scopusid | 전호수(57215293394) | * |
dc.date.modifydate | 20240311141405 | * |